Increased coronary events in depressed cardiovascular patients: 5-HT 2A receptor as missing link?

Psychosomatic Medicine

Volumn 65, Issue 5, 2003, Pages 729-737

  Schins, Annique ^b   Honig, Adriaan ^a   Crijns, Harrie ^b   Baur, Leo ^b   Hamulyak, Karly ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

5 HT2A receptor; Depression; Myocardial infarction; PF4; Platelet activation; Serotonin

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CALCIUM; NORTRIPTYLINE; PAROXETINE; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

CALCIUM MOBILIZATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG ANTAGONISM; HUMAN; ISCHEMIC HEART DISEASE; MAJOR DEPRESSION; MEDLINE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RECEPTOR SENSITIVITY; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ANTIDEPRESSIVE AGENTS; BLOOD PLATELETS; CALCIUM SIGNALING; CARDIOVASCULAR DISEASES; COMORBIDITY; DEPRESSION; DEPRESSIVE DISORDER; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, BIOLOGICAL; MYOCARDIAL ISCHEMIA; PLATELET ACTIVATION; PLATELET AGGREGATION; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN; THROMBOPHILIA;

EID: 0141523216     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PSY.0000088596.42029.10     Document Type: Review

References (94)

1. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-months survival. JAMA 1993;270:1819-25.
2. Ladwig KH, Kieser M, Konig J, Breithardt G, Borggrefe M. Affective disorders and survival after acute myocardial infarction (results from the post-infarction late potential study). Eur Heart J 1991;12:959-64.
3. Penninx BW, Beekman AT, Honig A, Deeg DJ, Schoevers RA, van Eijk JT, van Tilburg W. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 2001;58:221-7.
4. Jiang W, Alexander J, Christopher E, Kuchibhatla M, Gaulden L, Cuffe M, Blazing M, Davenport C, Califf R, Krishnan R, O'Connor CM. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001;161:1849-56.
5. Abramson J, Berger A, Krumholz HM, Vaccarino V. Depression and risk of heart failure among older persons with isolated systolic hypertension. Arch Intern Med 2001;161:1725-30.
6. Denollet J. Personality and mortality after myocardial infarction. Psychosom Med 1995;57:582-91.
7. Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996;93:1976-80.
8. Bush DE, Ziegelstein RC, Tayback M, Richter D, Stevens S, Zahalsky H, Fauerbach JA. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. Am J Cardiol 2001;88:337-41.
9. Ariyo AA, Haan M, Tangen CM, Rutledge JC, Cushman M, Dobs A, Furberg CD. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Circulation 2000;102:1773-9.
10. Welin C, Lappas G, Wilhelmsen L. Independent importance of psychosocial factors for prognosis after myocardial infarction. J Intern Med 2000;247:629-39.
11. Irvine J, Basinski A, Baker B, Jandciu S, Paquette M, Cairns J, Connolly S, Roberts R, Gent M, Dorian P. Depression and risk of sudden cardiac death after acute myocardial infarction: testing for the confounding effects of fatigue. Psychosom Med 1999;61:729-37.
12. Mayou RA, Gill D, Thompson DR, Day A, Hicks N, Volmink J, Neil A. Depression and anxiety as predictors of outcome after myocardial infarction. Psychosom Med 2000;62:212-9.
13. Lane D, Carroll D, Ring C, Beevers DG, Lip GY. Effects of depression and anxiety on mortality and quality-of-life 4 months after myocardial infarction. J Psychosom Res 2000;49:229-38.
14. Denollet J, Vaes J, Brutsaert DL. Inadequate response to treatment in coronary heart disease: adverse effects of type D personality and younger age on 5-year prognosis and quality of life. Circulation 2000;102:630-5.
15. Maes M, Meltzer HY. The serotonin hypothesis of major depression. New York: Raven Press; 1995.
16. Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 1994;40:288-95.
17. Staley JK, Malison RT, Innis RB. Imaging of the serotonergic system: interactions of neuroanatomical and functional abnormalities of depression. Biol Psychiatry 1998;44:534-49.
18. Yates M, Leake A, Candy JM, Fairbaim AF, McKeith IG, Ferrier IN. 5HT2 receptor changes in major depression. Biol Psychiatry 1990;27:489-96.
19. Hrdina PD, Demeter E, Vu TB, Sotonyi P, Palkovits M. 5-HT uptake sites and 5-HT2 receptors in brain of antidepressant-free suicide victims/depressives: increase in 5-HT2 sites in cortex and amygdala. Brain Res 1993;614:37-44.
20. Stanley M, Mann JJ. Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1983;1:214-6.
21. Mann JJ, Stanley M, McBride PA, McEwen BS. Increased serotonin2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry 1986;43:954-9.
22. Cheetham SC, Crompton MR, Katona CL, Horton RW. Brain 5-HT2 receptor binding sites in depressed suicide victims. Brain Res 1988;443:272-80.
23. Stockmeier CA, Dilley GE, Shapiro LA, Overholser JC, Thompson PA, Meltzer HY. Serotonin receptors in suicide victims with major depression. Neuropsychopharmacology 1997;16:162-73.
24. Lowther S, De Paermentier F, Crompton MR, Katona CL, Horton RW. Brain 5-HT2 receptors in suicide victims: violence of death, depression and effects of antidepressant treatment. Brain Res 1994;642:281-9.
25. Malison RT, Price LH, Berman R, van Dyck CH, Pelton GH, Carpenter L, Sanacora G, Owens MJ, Nemeroff CB, Rajeevan N, Baldwin RM, Seibyl JP, Innis RB, Charney DS. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 1998;44:1090-8.
26. Meyer JH, Kapur S, Houle S, DaSilva J, Owczarek B, Brown GM, Wilson AA, Kennedy SH. Prefrontal cortex 5-HT2 receptors in depression: an [18F]setoperone PET imaging study. Am J Psychiatry 1999;156:1029-34.
27. Yatham LN, Liddle PF, Shiah IS, Scarrow G, Lam RW, Adam MJ, Zis AP, Ruth TJ. Brain serotonin2 receptors in major depression: a positron emission tomography study. Arch Gen Psychiatry 2000;57:850-8.
28. Attar-Levy D, Martinot JL, Blin J, Dao-Castellana MH, Crouzel C, Mazoyer B, Poirier MF, Bourdel MC, Aymard N, Syrota A, Feline A. The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine. Biol Psychiatry 1999;45:180-6.
29. Biver F, Wikler D, Lotstra F, Damhaut P, Goldman S, Mendlewicz J. Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-insular cortex. Br J Psychiatry 1997;171:444-8.
30. Mayberg HS, Robinson RG, Wong DF, Parikh R, Bolduc P, Starkstein SE, Price T, Dannals RF, Links JM, Wilson AA, Ravert HT, Wagner HN. PET imaging of cortical S2 serotonin receptors after stroke: lateralized changes, and relationship to depression. Am J Psychiatry 1988;145:937-43.
31. D'Haenen H, Bossuyt A, Mertens J, Bossuyt-Piron C, Gijsemans M, Kaufman L. SPECT imaging of serotonin2 receptors in depression. Psychiatry Res 1992;45:227-37.
32. Ishida T, Hirata K, Sakoda T, Kawashima S, Akita H, Yokoyama M. Identification of mRNA for 5-HT1 and 5-HT2 receptor subtypes in human coronary arteries. Cardiovasc Res 1999;41:267-74.
33. Pakala R, Willerson JT, Benedict CR. Mitogenic effect of serotonin on vascular endothelial cells. Circulation 1994;90:1919-26.
34. Willerson JT, Yao SK, McNatt J, Benedict CR, Anderson HV, Golino P, Murphree SS, Buja LM. Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. Proc Natl Acad Sci USA 1991;88:10624-8.
35. Miyata K, Shimokawa H, Higo T, Yamawaki T, Katsumata N, Kandabashi T, Tanaka E, Takamura Y, Yogo K, Egashira K, Takeshita A. Sarpogrelate, a selective 5-HT2A serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model. J Cardiovasc Pharmacol 2000;35:294-301.
36. Nilsson T, Longmore J, Shaw D, Pantev E, Bard JA, Branchek T, Edvinsson L. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 1999;372:49-56.
37. Rosel P, Menchon JM, Vallejo J, Arranz B, Navarro MA, Liron F, Alvarez P. Platelet [3H]imipramine and [3H]paroxetine binding in depressed patients. J Affect Disord 1997;44:79-85.
38. Rosel P, Arranz B, Vallejo J, Alvarez P, Menchon JM, Palencia T, Navarro MA. Altered [3H]imipramine and 5-HT2 but not [3H]paroxetine binding sites in platelets from depressed patients. J Affect Disord 1999;52:225-33.
39. Pandey GN, Pandey SC, Janicak PG, Marks RC, Davis JM. Platelet serotonin-2 receptor binding sites in depression and suicide. Biol Psychiatry 1990;28:215-22.
40. Pandey GN, Pandey SC, Dwivedi Y, Sharma RP, Janicak PG, Davis JM. Platelet serotonin-2A receptors: a potential biological marker for suicidal behavior. Am J Psychiatry 1995;152:850-5.
41. Willerson JT. Serotonin and thrombotic complications. J Cardiovasc Pharmacol 1991;17(suppl):13-20.
42. Vikenes K, Farstad M, Nordrehaug JE. Serotonin is associated with coronary artery disease and cardiac events. Circulation 1999;100:483-9.
43. Schini-Kerth VB, Fisslthaler B, Van Obberghen-Schilling E, Busse R. Serotonin stimulates the expression of thrombin receptors in cultured vascular smooth muscle cells: role of protein kinase C and protein tyrosine kinases. Circulation 1996;93:2170-7.
44. Eckert A, Gann H, Riemann D, Aldenhoff J, Muller WE. Elevated intracellular calcium levels after 5-HT2 receptor stimulation in platelets of depressed patients. Biol Psychiatry 1993;34:565-8.
45. Konopka LM, Cooper R, Crayton JW. Serotonin-induced increases in platelet cytosolic calcium concentration in depressed, schizophrenic, and substance abuse patients. Biol Psychiatry 1996;39:708-13.
46. Delisi SM, Konopka LM, O'Connor FL, Crayton JW. Platelet cytosolic calcium responses to serotonin in depressed patients and controls: relationship to symptomatology and medication. Biol Psychiatry 1998;43:327-34.
47. Mendelson SD. The current status of the platelet 5-HT(2A) receptor in depression. J Affect Disord 2000;57:13-24.
48. von Känel R, Mills PJ, Fainman C, Dimsdale JE. Effects of psychological stress and psychiatric disorders on blood coagulation and fibrinolysis: a biobehavioral pathway to coronary artery disease? Psychosom Med 2001;63:531-44.
49. Gurney D, Lip GY, Blann AD. A reliable plasma marker of platelet activation: does it exist? Am J Hematol 2002;70:139-44.
50. Suzuki K, Kusumi I, Sasaki Y, Koyama T. Serotonin-induced platelet intracellular calcium mobilization in various psychiatric disorders: is it specific to bipolar disorder? J Affect Disord 2001;64:291-6.
51. Kusumi I, Koyama T, Yamashita I. Serotonin-induced platelet intracellular calcium mobilization in depressed patients. Psychopharmacology (Berl) 1994;113:322-7.
52. Bithell TC. The physiology of primary hemostasis. In: M. Wintrobe, editor. Wintrobe's Clinical Hematology, Vol. 1. London: Lea & Febiger; 1993. p. 540-55.
53. Gawaz M, Neumann FJ, Schomig A. Evaluation of platelet membrane glycoproteins in coronary artery disease: consequences for diagnosis and therapy. Circulation 1999;99:E1-E11.
54. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002;106:896-9.
55. Vanags DM, Rodgers SE, Duncan EM, Lloyd JV, Bochner F. Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline. Br J Pharmacol 1992;106:917-23.
56. Vanags DM, Lloyd JV, Rodgers SE, Bochner F. ADP, adrenaline and serotonin stimulate inositol 1,4,5-trisphosphate production in human platelets. Eur J Pharmacol 1998;358:93-100.
57. Dale GL, Friese P, Batar P, Hamilton SF, Reed GL, Jackson KW, Clemetson KJ, Alberio L. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature 2002;415:175-9.
58. Vanhoutte PM. Platelet-derived serotonin, the endothelium and cardiovascular disease. J Cardiovasc Pharmacol 1991;17(suppl 5):6-12.
59. Markovitz JH, Matthews KA. Platelets and coronary heart disease: potential psychophysiologic mechanisms. Psychosom Med 1991;53:643-68.
60. Malkoff SB, Muldoon MF, Zeigler ZR, Manuck SB. Blood platelet responsivity to acute mental stress. Psychosom Med 1993;55:477-82.
61. Markovitz JH, Matthews KA, Kiss J, Smitherman TC. Effects of hostility on platelet reactivity to psychological stress in coronary heart disease patients and in healthy controls. Psychosom Med 1996;58:143-9.
62. Markovitz JH. Hostility is associated with increased platelet activation in coronary heart disease. Psychosom Med 1998;60:586-91.
63. Laghrissi-Thode F, Wagner WR, Pollock BG, Johnson PC, Finkel MS. Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 1997;42:290-5.
64. Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000;20:137-40.
65. Kuijpers PMJC, Hamulyak K, Strik JMH, Wellens HJJ, Honig A. Beta-thromboglobulin and platelet factor 4 levels in post myocardial infarction patients with major depression. Psychiatry Res 2002;109:207-10.
66. Musselman DL, Tomer A, Manatunga AK, Knight BT, Porter MR, Kasey S, Marzec U, Harker LA, Nemeroff CB. Exaggerated platelet reactivity in major depression. Am J Psychiatry 1996;153:1313-7.
67. Musselman DL, Marzec UM, Manatunga A, Penna S, Reemsnyder A, Knight BT, Baron A, Hanson SR, Nemeroff CB. Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry 2000;57:875-82.
68. Markovitz JH, Shuster JL, Chitwood WS, May RS, Tolbert LC. Platelet activation in depression and effects of sertraline treatment: an open-label study. Am J Psychiatry 2000;157:1006-8.
69. Whyte EM, Pollock BG, Wagner WR, Mulsant BH, Ferrell RE, Mazumdar S, Reynolds CF 3rd. Influence of serotonin-transporter-linked promoter region polymorphism on platelet activation in geriatric depression. Am J Psychiatry 2001;158:2074-6.
70. Piletz JE, Zhu H, Madakasira S, Pazzaglia P, Lindsay DeVane C, Goldman N, Halaris A. Elevated P-selectin on platelets in depression: response to bupropion. J Psychiatr Res 2000;34:397-404.
71. Walsh MT, Dinan TG, Condren RM, Ryan M, Kenny D. Depression is associated with an increase in the expression of the platelet adhesion receptor glycoprotein Ib. Life Sci 2002;70:3155-65.
72. Musselman DL, Marzec U, Davidoff M, Manatunga AK, Gao F, Reemsnyder A, Duggirala S, Larsen H, Taylor RW, Hanson S, Nemeroff CB. Platelet activation and secretion in patients with major depression, thoracic aortic atherosclerosis, or renal dialysis treatment. Depress Anxiety 2002;15:91-101.
73. Serebruany VL, O'Connor CM, Gurbel PA. Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease. Am J Cardiol 2001;87:1398-400.
74. Gray JA, Roth BL. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull 2001;56:441-51.
75. Willerson JT, Eidt JF, McNatt J, Yao SK, Golino P, Anderson HV, Buja LM. Role of thromboxane and serotonin as mediators in the development of spontaneous alterations in coronary blood flow and neointimal proliferation in canine models with chronic coronary artery stenoses and endothelial injury. J Am Coll Cardiol 1991;17:B101-10.
76. Nugent DF, Dinan TG, Leonard BE. Further characterization of the inhibition of platelet aggregation by a plasma factor(s) in unmedicated unipolar depressed patients. J Affect Disord 1995;33:227-31.
77. McBride PA, Brown RP, DeMeo M, Keilp J, Mieczkowski T, Mann JJ. The relationship of platelet 5-HT2 receptor indices to major depressive disorder, personality traits, and suicidal behavior. Biol Psychiatry 1994;35:295-308.
78. Maes M, Van der Planken M, Van Gastel A, Desnyder R. Blood coagulation and platelet aggregation in major depression. J Affect Disord 1996;40:35-40.
79. Lederbogen F, Gilles M, Maras A, Hamann B, Colla M, Heuser I, Deuschle M. Increased platelet aggregability in major depression? Psychiatry Res 2001;102:255-61.
80. Shimbo D, Child J, Davidson K, Geer E, Osende JI, Reddy S, Dronge A, Fuster V, Badimon JJ. Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes. Am J Cardiol 2002;89:331-3.
81. Karege F, Bovier P, Rudolph W, Gaillard JM. Platelet phosphoinositide signaling system: an overstimulated pathway in depression. Biol Psychiatry 1996;39:697-702.
82. Rehavi M, Jerushalemi Z, Aviv A, Laor N, Podliszewski E, Karp L, Shavit S, Weizman R. Interaction between antidepressants and phosphoinositide signal transduction system in human platelets. Biol Psychiatry 1993;33:40-4.
83. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial [see comments]. Arch Gen Psychiatry 1999;56:407-12.
84. Bothwell RA, Eccleston D, Marshall E. Platelet intracellular calcium in patients with recurrent affective disorders. Psychopharmacology (Berl) 1994;114:375-81.
85. Kusumi I, Koyama T, Yamashita I. Serotonin-stimulated Ca2+ response is increased in the blood platelets of depressed patients. Biol Psychiatry 1991;30:310-2.
86. Mikuni M, Kagaya A, Takahashi K, Meltzer HY. Serotonin but not norepinephrine-induced calcium mobilization of platelets is enhanced in affective disorders. Psychopharmacology 1992;106:311-4.
87. Delisi JS, Konopka LM, Russell K, O'Connor FL, Cooper R, Crayton JW. Platelet cytosolic calcium hyperresponsivity to serotonin in patients with hypertension and depressive symptoms. Biol Psychiatry 1999;45:1035-41.
88. Dwivedi Y, Janicak PG, Pandey GN. Elevated [3H]inositol 1,4,5-trisphosphate binding sites and expressed inositol 1,4,5-trisphosphate receptor protein level in platelets of depressed patients. Psychopharmacology (Berl) 1998;138:47-54.
89. Tomiyoshi R, Kamei K, Muraoka S, Muneoka K, Takigawa M. Serotonin-induced platelet intracellular Ca2+ responses in untreated depressed patients and imipramine responders in remission. Biol Psychiatry 1999;45:1042-8.
90. Plein H, Berk M, Eppel S, Butkow N. Augmented platelet calcium uptake in response to serotonin stimulation in patients with major depression measured using Mn2+ influx and 45Ca2+ uptake. Life Sci 2000;66:425-31.
91. Trip MD, Cats VM, van Capelle FJ, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990;322:1549-54.
92. Amoroso G, van Veldhuisen DJ, Tio RA, Mariani M. Pathophysiology of vascular endothelium and circulating platelets: implications for coronary revascularisation and treatment. Int J Cardiol 2001;79:265-75.
93. Du L, Bakish D, Lapierre YD, Ravindran AV, Hrdina PD. Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder. Am J Med Genet 2000;96:56-60.
94. van den Brink RHS, van Melle J, Honig A, Schene AH, Crijns HJGM, Lambert FPG, Ormel J. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: Rationale and outline of the Myocardial Infarction and Depression-Intervention Trial (MIND-IT). Am Heart J 2002;144:219-25.